Prime Medicine Presents Preclinical Data Demonstrating

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by US FDA; data support advancement into Phase 1/2 clinical trial CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: […]

12 mins read

Prime Medicine Announces FDA Clearance of Investigational

First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD Initial Data Expected in 2025 CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative […]

9 mins read